Edwards Lifesciences (NYSE:EW – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.670-0.710 for the period, compared to the consensus EPS estimate of 0.690. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. Edwards Lifesciences also updated its Q3 guidance to $0.67-0.71 EPS.
Edwards Lifesciences Stock Up 4.5 %
NYSE:EW traded up $2.67 during midday trading on Friday, reaching $62.37. The company had a trading volume of 14,111,391 shares, compared to its average volume of 5,310,790. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market capitalization of $37.58 billion, a price-to-earnings ratio of 26.88, a PEG ratio of 2.22 and a beta of 1.11. The company has a current ratio of 3.71, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The stock’s fifty day simple moving average is $87.98 and its 200-day simple moving average is $86.84.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter last year, the company earned $0.66 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Edwards Lifesciences will post 2.73 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Insider Activity
In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the transaction, the vice president now directly owns 173,849 shares in the company, valued at approximately $14,639,824.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The disclosure for this sale can be found here. Insiders sold a total of 81,099 shares of company stock valued at $7,003,553 in the last 90 days. 1.29% of the stock is currently owned by insiders.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is a Secondary Public Offering? What Investors Need to Know
- MarketBeat Week in Review – 7/22 – 7/26
- What is the NASDAQ Stock Exchange?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.